NCT05605535 - Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

January 15, 2026

Study Completion Date

September 15, 2027

Conditions

Ovarian Neoplasm EpithelialOvarian CancerFallopian Tube NeoplasmsPeritoneal CarcinomaOvarian Serous Adenocarcinoma

Interventions

BIOLOGICAL

Oregovomab

2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

DRUG

Paclitaxel

175 mg/m\^2, every 3 weeks

DRUG

Carboplatin

AUC 5 or 6 IV Day 1 x 6 cycles (every 21 days)

BIOLOGICAL

Placebo

2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

Trial Locations (14)

221005

Institute of Medical Sciences, BHU, Varanasi

226003

King Georges Medical University, Lucknow

302022

Sri Ram Cancer Hospital, Jaipur

500004

MNJ Cancer Hospital, Hyderabad

530040

Omega Hospitals, Visakhapatnam

590010

KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Belagavi

602105

Saveetha Medical College and Hospitals, Chennai

605006

JIPMER, Puducherry

682041

Amrita Institute of Medical Sciences, Kochi

695011

Regional Cancer Centre, Medical College, Trivandrum

Unknown

King George Hospital, Visakhapatnam

Himalaya Cancer Hospital and Research Institute, Vadodara

Kailash Cancer Hospital and Research Centre, Vadodara

Sri Ramchandra Medical Centre, Chennai